Dermira, Inc. is a biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated therapies for dermatologic diseases. The Company's portfolio includes three late-stage product candidates that target unmet needs and market opportunities, such as Cimzia (certolizumab pegol), DRM04 and DRM01. Cimzia is an injectable biologic tumor necrosis factor-alpha inhibitor, or TNF inhibitor, that is approved and marketed for the treatment of numerous inflammatory diseases spanning multiple medical specialties, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and Crohn's disease. DRM04 is a topical, small-molecule anticholinergic product for the treatment of hyperhidrosis. DRM01 is a topical, small-molecule sebum inhibitor for the treatment of acne.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: DERM
- Previous Close: $33.32
- 50 Day Moving Average: $30.09
- 200 Day Moving Average: $31.82
- 52-Week Range: $17.42 - $36.34
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -13.89
- P/E Growth: 0.00
- Market Cap: $1.18B
- Outstanding Shares: 35,603,000
- Beta: 0.8
- Return on Equity: -51.30%
- Return on Assets: -42.90%
Companies Related to Dermira:
- Current Ratio: 9.53%
- Quick Ratio: 9.53%
What is Dermira's stock symbol?
Dermira trades on the NASDAQ under the ticker symbol "DERM."
Where is Dermira's stock going? Where will Dermira's stock price be in 2017?
5 equities research analysts have issued 12 month price objectives for Dermira's shares. Their predictions range from $40.00 to $47.00. On average, they anticipate Dermira's share price to reach $44.75 in the next twelve months.
When will Dermira announce their earnings?
Dermira is scheduled to release their next quarterly earnings announcement on Wednesday, March, 1st 2017.
Who owns Dermira stock?
Dermira's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include FMR LLC (13.23%), UCB SA (7.50%), State Street Corp (1.44%), Loomis Sayles & Co. L P (1.21%), Orbimed Advisors LLC (1.20%) and Perceptive Advisors LLC (0.91%). Company insiders that own Dermira stock include Andrew Guggenhime, Christopher M Griffith, Eugene A Bauer, Luis C Pena, Thomas G Wiggans and William R Ringo.
Who sold Dermira stock? Who is selling Dermira stock?
Dermira's stock was sold by a variety of institutional investors in the last quarter, including EcoR1 Capital LLC, State Street Corp, Century Capital Management LLC, Fred Alger Management Inc., Nicholas Investment Partners LP, Acuta Capital Partners LLC, Allianz Asset Management AG and Boothbay Fund Management LLC. Company insiders that have sold Dermira stock in the last year include Andrew Guggenhime, Christopher M Griffith, Eugene A Bauer, Luis C Pena, Thomas G Wiggans and William R Ringo.
Who bought Dermira stock? Who is buying Dermira stock?
Dermira's stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, Perceptive Advisors LLC, Novo A S, New Leaf Venture Partners L.L.C., Clough Capital Partners L P, Loomis Sayles & Co. L P, Marshall Wace LLP and Advisory Research Inc..
How do I buy Dermira stock?
Shares of Dermira can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Dermira stock cost?
One share of Dermira stock can currently be purchased for approximately $33.20.